A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

Inclusion Criteria: * Age above 18 years old (including 18 years old)，regardless of gender； * ECOG-PS score of 0-1,； * expected survival≥12 weeks； * There was no tumor deterioration in the 2 weeks prior to study drug treatment. * Advanced non-small cell lung cancer without systemic chemotherapy. * At least one tumor lesion with a maximum diameter ≥10 mm (short diameter ≥15 mm if it is a lymph node) that could be measured accurately at baseline according to RECIST1.1 criteria. Baseline tumor imaging was performed within 28 days before the first dose. * Women of childbearing age should use appropriate contraception and should not breastfeed from screening until 3 months after discontinuation of study treatment. * Male subjects should use barrier contraception (i.e., condoms) for 3 months from screening until discontinuation of study treatment. * All subjects voluntarily participated and signed the informed consent form in person. Exclusion Criteria: * Uncontrolled ischemic heart disease or clinically significant congestive heart failure (NYHA class III or IV); * stroke or cardio-cerebrovascular event within 6 months before enrollment; * QTcF interval \> 480msec at screening or \> 500msec for patients with implanted ventricular pacemakers; * Previous hematopoietic stem cell or bone marrow transplantation; * Allergy to the study drug or its components; * Others considered by the investigator to be unsuitable for this study.